Holly Elizabeth Rawizza, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ritonavir | 5 | 2024 | 328 | 1.980 |
Why?
|
| Rifabutin | 3 | 2024 | 58 | 1.800 |
Why?
|
| Antibiotics, Antitubercular | 2 | 2019 | 101 | 0.800 |
Why?
|
| HIV Infections | 16 | 2024 | 17159 | 0.800 |
Why?
|
| Tuberculosis | 5 | 2024 | 2003 | 0.780 |
Why?
|
| Zidovudine | 3 | 2017 | 624 | 0.730 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2017 | 1349 | 0.630 |
Why?
|
| Lost to Follow-Up | 2 | 2015 | 124 | 0.580 |
Why?
|
| Whipple Disease | 1 | 2016 | 20 | 0.550 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 4492 | 0.530 |
Why?
|
| HIV Protease Inhibitors | 2 | 2024 | 432 | 0.460 |
Why?
|
| Endophthalmitis | 1 | 2016 | 257 | 0.450 |
Why?
|
| Nigeria | 8 | 2023 | 762 | 0.440 |
Why?
|
| Chemoprevention | 1 | 2015 | 326 | 0.410 |
Why?
|
| Endocarditis | 1 | 2016 | 351 | 0.400 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 1780 | 0.370 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 623 | 0.360 |
Why?
|
| HIV-1 | 4 | 2023 | 6850 | 0.290 |
Why?
|
| Salvage Therapy | 1 | 2013 | 1266 | 0.280 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2017 | 2127 | 0.270 |
Why?
|
| Drug Monitoring | 1 | 2011 | 966 | 0.250 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2019 | 1894 | 0.230 |
Why?
|
| Viral Load | 4 | 2023 | 3323 | 0.170 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 409 | 0.160 |
Why?
|
| Sulfonamides | 1 | 2008 | 1973 | 0.160 |
Why?
|
| Rifampin | 1 | 2019 | 341 | 0.140 |
Why?
|
| Orchitis | 1 | 2016 | 35 | 0.140 |
Why?
|
| Epididymitis | 1 | 2016 | 37 | 0.140 |
Why?
|
| Ceftriaxone | 1 | 2016 | 175 | 0.130 |
Why?
|
| Lamivudine | 1 | 2017 | 363 | 0.130 |
Why?
|
| Drug Interactions | 1 | 2019 | 1426 | 0.120 |
Why?
|
| Nevirapine | 1 | 2015 | 273 | 0.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2017 | 618 | 0.120 |
Why?
|
| Vancomycin | 1 | 2017 | 503 | 0.110 |
Why?
|
| Myositis | 1 | 2016 | 269 | 0.110 |
Why?
|
| Endocarditis, Bacterial | 1 | 2017 | 445 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 6499 | 0.110 |
Why?
|
| Drug Resistance, Viral | 2 | 2017 | 859 | 0.100 |
Why?
|
| Arthritis | 1 | 2016 | 666 | 0.090 |
Why?
|
| Infant | 4 | 2024 | 36030 | 0.090 |
Why?
|
| Sputum | 1 | 2013 | 503 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 695 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2015 | 2569 | 0.080 |
Why?
|
| Male | 13 | 2024 | 359413 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2013 | 1006 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 7400 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 1405 | 0.080 |
Why?
|
| Humans | 18 | 2024 | 760261 | 0.070 |
Why?
|
| Child | 4 | 2024 | 79758 | 0.070 |
Why?
|
| Female | 11 | 2024 | 391011 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 1266 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2024 | 42034 | 0.060 |
Why?
|
| Adult | 8 | 2023 | 219847 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2015 | 2163 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2019 | 64947 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2019 | 80301 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2019 | 26168 | 0.050 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 39 | 0.040 |
Why?
|
| Phylogeography | 1 | 2020 | 72 | 0.040 |
Why?
|
| Developing Countries | 1 | 2011 | 2880 | 0.040 |
Why?
|
| Genotype | 1 | 2013 | 12959 | 0.040 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2017 | 212 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 607 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14656 | 0.030 |
Why?
|
| Plasma | 1 | 2019 | 584 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 15273 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 14482 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 41317 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2020 | 1526 | 0.030 |
Why?
|
| Demography | 1 | 2020 | 1650 | 0.030 |
Why?
|
| Adolescent | 2 | 2021 | 87747 | 0.030 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2017 | 491 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 1208 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2019 | 2024 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39254 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2020 | 1739 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2020 | 2698 | 0.030 |
Why?
|
| Pregnancy | 1 | 2015 | 29725 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 2775 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 642 | 0.020 |
Why?
|
| Middle Aged | 3 | 2023 | 220175 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2325 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2017 | 2646 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 1884 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 1295 | 0.020 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 330 | 0.020 |
Why?
|
| Bone Density | 1 | 2023 | 3528 | 0.020 |
Why?
|
| Fever | 1 | 2017 | 1618 | 0.020 |
Why?
|
| Vitamin D | 1 | 2023 | 3293 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 1174 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 1462 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 29950 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2013 | 1455 | 0.020 |
Why?
|
| Echocardiography | 1 | 2017 | 4980 | 0.010 |
Why?
|
| Prevalence | 1 | 2020 | 15687 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2013 | 1905 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 25928 | 0.010 |
Why?
|
| Lung | 1 | 2017 | 9989 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 54263 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 58673 | 0.010 |
Why?
|